Monday, May 29, 2023
English News
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
    • Rewind
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
  • Rewind
Home | Hyderabad | Bharat Biotech Gearing Up To Meet Demand As Covaxin Gets Dcgi Nod

Bharat Biotech gearing up to meet demand as Covaxin gets DCGI nod

"Following the emergency use permission, the company is in a position to meet any production requirement that the government may have at this time,” company officials said

By Telangana Today
Updated On - 12:38 AM, Mon - 4 January 21
Bharat Biotech gearing up to meet demand as Covaxin gets DCGI nod
whatsapp facebook twitter telegram

Hyderabad: Hyderabad-based vaccine maker Bharat Biotech, which received the Drugs Controller General of India (DCGI) nod for emergency use of its Covid-19 vaccine ‘Covaxin’, is gearing up to meet the vaccine needs of the country. “Following the emergency use permission, the company is in a position to meet any production requirement that the government may have at this time,” company officials said.

On receiving permission from the government, Bharat Biotech CMD Dr Krishna Ella said: “The approval of Covaxin for emergency use is a giant leap for innovation and novel product development in India. While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most. Covaxin has generated excellent safety data with robust immune responses to multiple viral proteins that persist,”

The Subject Expert Committee (SEC) of Central Drugs Standards Control Organization (CDSCO) makes recommendations in respect of Accelerated Approval Process requests. The Subject Expert Committee of CDSCO met on January 1 and 2 and made the recommendation for the consideration and final decision of the DCGI.

Covaxin is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a vero cell manufacturing platform with safety track record of more than 300 million doses. In case of need, the capacity is expandable to 500 million doses.

The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers across India. Bharat Biotech on Saturday crossed 23,000 volunteer mark and expects to recruit all 26,000 volunteers by early this week. The company said the phase III trials could be concluded by mid-February 2021 and by June-July 2021, the vaccine is likely to be ready for marketing.

Covaxin has been evaluated in about 1,000 subjects in phase I and phase II clinical trials, with promising safety and immunogenicity results, with acceptance in international peer reviewed scientific journals. The publication of phase II trial data is undergoing the peer review process, according to the company.

Bharat Biotech is developing Covaxin along with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s Bio-Safety Level-3 bio-containment facility.

The company said that evaluation of Covaxin has resulted in several product characteristics including long-term persistence of immune responses to multiple viral proteins, and has demonstrated broad spectrum neutralising capability with heterologous SARS-CoV2 strains, thus potentially reducing or eliminating escape mutants.

Also read:

India approves 2 Covid vaccines for emergency use

Expert panel recommends Bharat Biotech’s ‘Covaxin’ for emergency use

 

  • Follow Us :
  • Tags
  • Bharat Biotech
  • Bharat Biotech CMD
  • Central Drugs Standards Control Organization
  • company officials

Related News

  • Research allows more insight into post-vaccine heart inflammation cases

    Research allows more insight into post-vaccine heart inflammation cases

  • India logs 1,690 Covid infections in a day; active cases below 20,000

    India logs 1,690 Covid infections in a day; active cases below 20,000

  • Genome Valley: Home to Asia’s largest life sciences cluster

    Genome Valley: Home to Asia’s largest life sciences cluster

  • Hackers stole source code, installed malware: GoDaddy

    Hackers stole source code, installed malware: GoDaddy

  • Krishna Ella releases book on ‘Economics of Covid-19’

    Krishna Ella releases book on ‘Economics of Covid-19’

  • India’s first intranasal Covid vaccine iNNCOVACC launched

    India’s first intranasal Covid vaccine iNNCOVACC launched

Latest News

  • Olivier Giroud’s header secures Champions League spot for AC Milan

    12 mins ago
  • Kareena Kapoor adds glamour to Monaco Grand Prix 2023

    27 mins ago
  • Excise Policy scam: Manish Sisodia generated Rs 622.67 cr POC, says ED

    1 min ago
  • Devotees express anger over Yamuna River’s pathetic state ahead of Ganga Dussehra

    9 mins ago
  • Canal water in Venice turns fluorescent green, authorities launch probe

    15 mins ago
  • Formula 1: Verstappen wins Monaco Grand Prix

    30 mins ago
  • Congress slams Centre for ‘breakdown’ of law and order in Manipur

    36 mins ago
  • Government hospitals first choice for poor in Telangana

    2 hours ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam